pLC-Flag-CSNK1A1 G40N-Puro Citations (1)

Originally described in: CK1alpha and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A, Manzano M, Gottwein E Blood. 2018 Aug 9;132(6):577-586. doi: 10.1182/blood-2018-01-828418. Epub 2018 Jun 28. PubMed Journal

---

Articles Citing pLC-Flag-CSNK1A1 G40N-Puro

Articles

Selective CK1alpha degraders exert antiproliferative activity against a broad range of human cancer cell lines. Nishiguchi G, Mascibroda LG, Young SM, Caine EA, Abdelhamed S, Kooijman JJ, Miller DJ, Das S, McGowan K, Mayasundari A, Shi Z, Barajas JM, Hiltenbrand R, Aggarwal A, Chang Y, Mishra V, Narina S, Thomas M, Loughran AJ, Kalathur R, Yu K, Zhou S, Wang X, High AA, Peng J, Pruett-Miller SM, Daniels DL, Urh M, Shelat AA, Mullighan CG, Riching KM, Zaman GJR, Fischer M, Klco JM, Rankovic Z. Nat Commun. 2024 Jan 16;15(1):482. doi: 10.1038/s41467-024-44698-1. PubMed

If you have published an article using this material, please email us at to have your article added to this page.